肺动脉高压患者COVID-19相关死亡率的趋势:COMPERA分析
在肺动脉高压患者中,随着奥密克戎变异株的出现,COVID-19相关死亡率大幅下降。早期小样本系列报告病死率为19–45%,法国211例前瞻性系列总体病死率为24.6%。
要点
- 肺动脉高压患者COVID-19病死率随奥密克戎变异株出现而显著下降
- 早期小样本(11–70例)报告病死率19–45%
- 法国211例前瞻性系列(2020年2月至2021年4月)病死率24.6%
核心结论
- 肺动脉高压患者中,COVID-19相关死亡率随奥密克戎变异株出现而大幅下降。
研究设计与样本
- COMPERA分析,基于肺动脉高压患者队列,比较不同时期COVID-19相关死亡率趋势。
主要发现
- 早期小样本系列(11–70例肺动脉高压患者)报告COVID-19病死率为19–45%。
- 法国211例各种类型肺动脉高压患者前瞻性系列(2020年2月至2021年4月感染COVID-19)总体病死率为24.6%。
- 奥密克戎变异株出现后,肺动脉高压患者COVID-19相关死亡率大幅下降。
临床怎么用
- 临床医生应认识到肺动脉高压患者COVID-19相关死亡风险随变异株演变而变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants https://bit.ly/42OMsfj Patients with pulmonary hypertension (PH) have been among those affected heavily by the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Early case series reported case fatality rates ranging from 19–45% in small series of 11–70 patients with PH who contracted COVID-19 [1–4]. A prospective series of 211 French patients with various forms of PH, who developed COVID-19 between February 2020 and April 2021, found an overall case fatality rate of 24.6% [5].
引用
- Schmidt KH, Milger K, Pausch C, et al. Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis. Eur Respir J. 2023. PMID: 37105586. doi:10.1183/13993003.02440-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。